Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02804178 · ClinicalTrials.gov registry record · Phase 2
A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia
A Phase 2 study, sponsored by Millendo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02804178 is a Phase 2 study that has completed, run by Millendo Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT02804178, a Phase 2 study, has completed, sponsored by Millendo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a Phase 2 multicenter, single-blind, multiple dose study to evaluate the safety and efficacy of orally administered ATR-101 in subjects with classic congenital adrenal hyperplasia (CAH). Treatment duration will range from a minimum of approximately 2 months to 6 months per subject. A subject may receive a minimum of one dose level or up to a maximum of 5 dose levels, in sequentially increasing dose strengths. Each dose level will last 28 days.
Interventions
- DRUG ATR-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-05-18 |
| Est. Completion | 2017-08-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02804178
The ClinicalTrials.gov registry entry for NCT02804178 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millendo Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATR-101 is the first listed.
NCT02804178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02804178 about?
NCT02804178 is a clinical study titled "A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia". This is a Phase 2 multicenter, single-blind, multiple dose study to evaluate the safety and efficacy of orally administered ATR-101 in subjects with classic congenital adrenal hyperplasia (CAH). Treatment duration will range from a minimum of approximately 2 months to 6 months per subject. A subject...
What is the current status of trial NCT02804178?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2016-05-18. Estimated completion is 2017-08-17.
What interventions are being tested in trial NCT02804178?
The interventions under investigation include: ATR-101 (DRUG).
Who is sponsoring clinical trial NCT02804178?
This trial is sponsored by Millendo Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.